…
Aurora Spine Corporation, through its subsidiary, Aurora Spine, Inc., engages in the development and distribution of minimally invasive interspinous fusion systems and devices in Canada. The company offers interspinous process lumbar fusion devices, such as the ZIP, ZIP ULTR, ZIP LP, and ZIP-51 for patients suffering from degenerative disc diseases. It also provides SOLO, an anterior lumbar interbody fusion 3D printed stand-alone lumbar fusion device, which is an integrated plate and spacer system that helps to preserve the natural anatomic profile while providing spinal column support and stability; and SiLo, a posterior allograft implant; and SiLO TFX, a titanium implant device for sacroiliac joint fusion. In addition, the company offers Dexa-C, a 3D printed cervical fusion device, which is a porous 3D-printed intervertebral cage that incorporates lattice pattern options to support the matching of patients' bone quality, as well as DEXA SOLO-L, a spinal device implanted in the intervertebral body space. Further, it provides TiNano, which offers a product line of lumbar fusion devices. The company was founded in 2013 and is headquartered in Toronto, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Aurora Spine Corp develops minimally invasive expandable interbody spinal implants and related surgical instruments for fusion procedures. Long-term growth may be supported by aging populations, wider adoption of minimally invasive spine techniques and successful expansion of clinical adoption and distribution. The company may appear positioned to benefit if regulatory approvals and commercial execution progress.
Material risks include limited commercial scale and liquidity as a small-cap medical device company, regulatory and reimbursement uncertainty, strong competition from established spine-device manufacturers and execution risk in converting clinical interest into sustained sales.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Income before tax | -1.00M | -1.68M | -1.50M | -2.36M | -0.23M |
| Net income | -1.00M | -1.68M | -1.50M | -2.36M | -0.23M |
| Selling general administrative | 9.57M | 6.82M | 6.08M | 4.99M | 3.65M |
| Selling and marketing expenses | - | 0.72M | 1.05M | 0.80M | 0.11M |
| Gross profit | 10.63M | 8.21M | 7.81M | 4.83M | 3.47M |
| Reconciled depreciation | 1.01M | 1.05M | 0.87M | 0.65M | 0.59M |
| Ebit | - | -1.50M | -1.28M | -2.55M | -1.16M |
| Ebitda | - | -0.45M | -0.41M | -1.90M | -0.57M |
| Depreciation and amortization | - | 1.05M | 0.87M | 0.65M | 0.59M |
| Operating income | -0.67M | -1.50M | -1.57M | -2.71M | -1.25M |
| Other operating expenses | - | 16.02M | 16.22M | 13.10M | 9.81M |
| Interest expense | 0.18M | 0.19M | 0.16M | 0.16M | 0.09M |
| Net interest income | -0.18M | -0.19M | -0.16M | -0.16M | -0.09M |
| Income tax expense | - | 0.88M | 0.23M | 0.16M | 0.09M |
| Total revenue | 17.56M | 14.52M | 14.88M | 10.54M | 8.65M |
| Total operating expenses | 18.24M | 9.71M | 9.15M | 7.38M | 4.63M |
| Cost of revenue | 6.93M | 6.31M | 7.07M | 5.71M | 5.18M |
| Total other income expense net | -0.15M | -0.19M | 0.01M | 0.35M | 1.02M |
| Net income from continuing ops | -1.00M | -1.68M | -1.50M | -2.36M | -0.23M |
| Net income applicable to common shares | - | - | - | -2.36M | -0.23M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 11.67M | 11.99M | 10.12M | 10.56M | 7.16M |
| Intangible assets | 0.80M | 0.75M | 0.88M | 0.85M | 0.87M |
| Other current assets | - | 0.20M | - | - | - |
| Total liab | 7.28M | 6.69M | 5.81M | 4.99M | 3.87M |
| Total stockholder equity | 4.40M | 5.30M | 4.32M | 5.57M | 3.28M |
| Other current liab | 0.00M | - | - | - | - |
| Common stock | - | 27.66M | - | 25.09M | 22.01M |
| Capital stock | 27.66M | 27.66M | 25.22M | 25.09M | 22.01M |
| Retained earnings | -26.78M | -25.78M | -24.09M | -22.59M | -20.23M |
| Cash | 0.78M | 0.77M | 0.42M | 3.17M | 1.71M |
| Total current liabilities | 3.88M | 3.27M | 3.03M | 2.63M | 1.56M |
| Net debt | 1.93M | 2.88M | 1.99M | - | 0.46M |
| Short term debt | - | 0.23M | - | - | - |
| Short long term debt | - | - | - | 0.01M | 0.03M |
| Short long term debt total | - | 3.65M | - | - | - |
| Other stockholder equity | - | 3.42M | - | 3.08M | 1.51M |
| Property plant equipment | - | - | - | 1.30M | 1.09M |
| Total current assets | 8.50M | 8.50M | 7.33M | 8.41M | 5.20M |
| Net tangible assets | - | - | - | 4.71M | 2.41M |
| Net receivables | 3.14M | 3.97M | 3.67M | 2.67M | 1.66M |
| Long term debt | 2.71M | 2.56M | 2.42M | 2.27M | 2.14M |
| Inventory | 3.61M | 3.56M | 3.05M | 1.89M | 1.60M |
| Accounts payable | 1.76M | 3.04M | 2.83M | 2.45M | 1.53M |
| Non currrent assets other | -0.00M | 0.45M | - | - | - |
| Non current assets total | 3.17M | 3.48M | 2.79M | 2.16M | 1.96M |
| Capital lease obligations | 0.97M | 1.08M | 0.55M | 0.09M | 0.17M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Investments | -0.48M | -0.48M | -0.87M | -0.72M | -0.55M |
| Change to liabilities | - | - | - | 1.04M | -0.40M |
| Total cashflows from investing activities | - | - | - | -0.72M | -0.55M |
| Net borrowings | -0.36M | - | - | -0.19M | -0.14M |
| Total cash from financing activities | -0.36M | 1.76M | -0.32M | 4.31M | 1.51M |
| Change to operating activities | - | - | - | -0.44M | 0.03M |
| Net income | -1.00M | -1.68M | -1.50M | -2.36M | -0.23M |
| Change in cash | 0.06M | 0.34M | -2.75M | 1.46M | 1.27M |
| Begin period cash flow | 0.77M | 0.42M | 3.17M | 1.71M | 0.44M |
| End period cash flow | 0.83M | 0.77M | 0.42M | 3.17M | 1.71M |
| Total cash from operating activities | 0.90M | -0.94M | -1.56M | -2.13M | 0.31M |
| Issuance of capital stock | 0.00M | 1.41M | 0.00M | 5.12M | 1.70M |
| Depreciation | 1.01M | 1.05M | 0.87M | 0.65M | 0.59M |
| Change to inventory | -0.05M | -0.51M | -1.16M | -0.33M | -0.32M |
| Change to account receivables | - | - | - | -1.01M | 0.78M |
| Other cashflows from financing activities | - | -0.07M | 0.10M | -0.64M | -0.08M |
| Change to netincome | - | - | - | 0.33M | -0.14M |
| Capital expenditures | 0.64M | 0.48M | 0.87M | 0.72M | 0.55M |
| Change in working capital | 0.62M | -0.62M | -1.36M | -0.74M | 0.10M |
| Stock based compensation | 0.10M | 0.14M | 0.14M | 0.14M | 0.09M |
| Other non cash items | 0.17M | 0.18M | 0.23M | 0.14M | -0.49M |
| Free cash flow | 0.27M | -1.41M | -2.43M | -2.85M | -0.25M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(CAD) |
Price
(CAD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ASG Aurora Spine Corp |
-0.01 13.04% |
0.10 | - | - | 1.19 | 4.07 | 1.02 | 202.96 |
| TLT Theralase Technologies Inc. |
0.01 2.78% |
0.18 | - | - | 90.07 | 82.51 | 90.31 | -12.06 |
| CNVI Conavi Medical Corp. |
-0.01 4.55% |
0.10 | - | - | 66.65 | - | 95.30 | - |
| PINK Perimeter Medical Imaging AI Inc |
- -% |
0.18 | 4.13 | - | 18.78 | 11.34 | 20.22 | -2.55 |
| CHER Cheelcare Inc. |
- -% |
1.25 | - | - | 20.92 | 106.42 | 21.26 | - |
Aurora Spine Corporation, through its subsidiary, Aurora Spine, Inc., engages in the development and distribution of minimally invasive interspinous fusion systems and devices in Canada. The company offers interspinous process lumbar fusion devices, such as the ZIP, ZIP ULTR, ZIP LP, and ZIP-51 for patients suffering from degenerative disc diseases. It also provides SOLO, an anterior lumbar interbody fusion 3D printed stand-alone lumbar fusion device, which is an integrated plate and spacer system that helps to preserve the natural anatomic profile while providing spinal column support and stability; and SiLo, a posterior allograft implant; and SiLO TFX, a titanium implant device for sacroiliac joint fusion. In addition, the company offers Dexa-C, a 3D printed cervical fusion device, which is a porous 3D-printed intervertebral cage that incorporates lattice pattern options to support the matching of patients' bone quality, as well as DEXA SOLO-L, a spinal device implanted in the intervertebral body space. Further, it provides TiNano, which offers a product line of lumbar fusion devices. The company was founded in 2013 and is headquartered in Toronto, Canada.
| Name | Title | Year Born |
|---|---|---|
| Mr. Trent J. Northcutt | Founder, Pres, CEO & Director | 1967 |
| Mr. Chad Clouse | Chief Financial Officer | NA |
| Mr. Laszlo Garamszegi | CTO & Founder | 1971 |
| Mr. David M. Meyer | VP, Chief Legal Officer & Sec. | NA |
| Mr. Trent J. Northcutt | Founder, President, CEO & Director | 1967 |
| Mr. David M. Meyer | VP, Chief Legal Officer & Secretary | NA |
| Matthew Goldstone | Chief Commercial Officer | NA |
| Mr. Matt Paxton | Executive Vice President of Sales | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.